Felipe Batalini

May 21, 2024 | nature.com | Yered Pita-Juarez |Felipe Batalini |Shivani Nanda |Frank J. Slack |Xanthi-Lida Katopodi |Eleni Kanata | +2 more

AbstractThe landscape of non-coding mutations in cancer progression and immune evasion is largely unexplored. Here, we identify transcrptome-wide somatic and germline 3′ untranslated region (3′-UTR) variants from 375 gastric cancer patients from The Cancer Genome Atlas.

Apr 15, 2024 | nature.com | Fabin Dang |Lin Wang |Wenxue Li |Felipe Batalini |Jaymin Patel |John G. Clohessy | +4 more

AbstractInduced oncoproteins degradation provides an attractive anti-cancer modality. Activation of anaphase-promoting complex (APC/CCDH1) prevents cell-cycle entry by targeting crucial mitotic proteins for degradation. Phosphorylation of its co-activator CDH1 modulates the E3 ligase activity, but little is known about its regulation after phosphorylation and how to effectively harness APC/CCDH1 activity to treat cancer.

Mar 21, 2024 | medrxiv.org | Amara Tariq |Felipe Batalini |Avisha Das |Boddhisattwa Dhara

The authors have declared no competing interest. This study was funded by NIH/NCI, U01 CA269264-01-1, Flexible NLP toolkit for automatic curation ofoutcomes for breast cancer patients (PI: Banerjee). I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Nov 10, 2023 | mdpi.com | Suganya Karikalan |Felipe Batalini |Farah Raheem |Aya El Masry

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Jul 10, 2023 | cco.amegroups.org | Felipe Batalini |Laercio Lopes DaSilva |Leticia Campoverde |Bruno Carvalho

Original Article Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis Felipe Batalini, Laercio Lopes DaSilva, Leticia Campoverde, Ana Carolina Marin Comini, Bruno Murad Carvalho, Wilson Nogueira, Hyan Silveira, Brenda J. Ernst, Lida A. Mina